Wren

Why are different medicines used for bipolar lows, highs and staying well?

Because lifting a low, settling a high and keeping the next episode away are different treatment aims, and a medicine can work better for one than another.

Several choices are well established for each aim. A useful choice also considers previous benefit, side effects and the protection needed after the present episode settles. Studies lasting a few weeks answer a different question from longer prevention studies; the person's experience of taking the medicine helps bring those answers together.⁠

What the medicine is being asked to do

During a low, the question is whether the medicine helps depression lift. During a high, it is whether it brings excessive energy, sleeplessness and other high symptoms down. Between episodes, the question is whether it keeps another low or high away over months or years. Treatment guidelines weigh these aims separately, along with risks and how manageable the side effects are in ordinary life.⁠

Some medicines cover several aims. Quetiapine is a well-established option for lows, highs and staying well. Lithium is well established for highs and staying well and is also an option for lows; Living with lithium explains taking it. Lamotrigine has its main place in lows and longer-term protection, especially against depression; Living with lamotrigine explains its use. These differences explain why a medicine may be kept for protection while another is added to treat the present episode.⁠

How the treatment period changes the answer

Most trials of medicines for a current episode last weeks. Lurasidone, lumateperone and cariprazine are medicines used for bipolar lows. The trials behind lurasidone and lumateperone largely assessed benefit after six weeks. Cariprazine trials also assessed benefit at six weeks even when treatment continued longer. Trials of risperidone and asenapine for mania, a severe high, commonly assessed symptoms after three weeks. Both medicines are used to settle highs. These studies answer whether symptoms improve during that treatment period.⁠

Longer-term trials sometimes first find people who improve on a medicine, then compare continuing it with switching to a pill without active medicine. Asenapine's prevention study used this approach. Its result is particularly relevant to someone who has already improved on and tolerated asenapine. The person's previous response is therefore useful evidence in a medication discussion. Working out a choice about bipolar medicine gives prompts for bringing that experience into the conversation.⁠

Comparing choices for the present aim

A useful comparison starts with the present aim, the person's previous episodes and responses, and the effects on sleep, energy and ordinary life. For example, lifting a low and avoiding weight gain may matter most now, while protection against repeated highs remains a longer-term need. Medicines for bipolar explains benefits and daily downsides; the prescriber, the professional responsible for the prescription, can use those priorities to weigh a change and the protection needed during it.⁠

Sources

  1. 1Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Published October 2023.
  2. 2Yatham LN et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Published 14 March 2018.
  3. 3LATUDA (lurasidone hydrochloride) tablets, for oral use Lurasidone
  4. 4CAPLYTA® (lumateperone) capsules, for oral use Lumateperone
  5. 5VRAYLAR® (cariprazine) capsules, for oral use Cariprazine
  6. 6RISPERDAL® (risperidone) tablets, for oral use Risperidone
  7. 7SAPHRIS® (asenapine) sublingual tablets Asenapine study

Last updated 12 October 2026